A Japanese Bioventure Company's Application of Stem Cell Technology in Regenerative Medicine

Masanori Sawada; Daisuke Sugiyama; Takenobu Nii; Katsuhiro Konno; Hardy T S Kagimoto

doi:10.1016/j.clinthera.2018.10.001

A Japanese Bioventure Company's Application of Stem Cell Technology in Regenerative Medicine

Clin Ther. 2018 Nov;40(11):1801-1806. doi: 10.1016/j.clinthera.2018.10.001. Epub 2018 Nov 3.

Authors

Masanori Sawada¹, Daisuke Sugiyama², Takenobu Nii³, Katsuhiro Konno³, Hardy T S Kagimoto⁴

Affiliations

¹ Healios K.K, Tokyo, Japan. Electronic address: m.sawada@healios.jp.
² Incubation Center for Advanced Medical Science, Kyushu University, Fukuoka, Japan; Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
³ Incubation Center for Advanced Medical Science, Kyushu University, Fukuoka, Japan.
⁴ Healios K.K, Tokyo, Japan.

PMID: 30396514
DOI: 10.1016/j.clinthera.2018.10.001

Abstract

Regenerative medicine mediated by the transplantation of somatic stem cells and functional cells derived from induced pluripotent stem cells has great potential in the treatment of currently incurable diseases and thus has attracted significant public attention. To put this into practice, several functional cell lines were developed and laws regarding regenerative medicine were put in force in Japan. In this report, we introduce recent efforts of a bioventure company with special attention to the case of Healios K.K.

Keywords: cell medicine; iPS cells; regenerative medicine; somatic stem cells.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Induced Pluripotent Stem Cells / cytology*
Japan
Regenerative Medicine*